PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Cited By ~ 2

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

10.1158/1538-7445.sabcs20-pd3-11 ◽

2021 ◽

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Taira Naruto ◽

Norikazu Masuda ◽

Masato Takahashi ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)

10.1158/1538-7445.sabcs15-ot3-01-01 ◽

2016 ◽

Author(s):

K Miller ◽

J Cortes ◽

SA Hurvitz ◽

IE Krop ◽

D Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.357 ◽

2018 ◽

Vol 29 ◽

pp. viii121 ◽

Cited By ~ 1

Author(s):

S. Loibl ◽

O. Metzger ◽

S.J. Mandrekar ◽

C. Mundhenke ◽

S. Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

Cancer Research and Treatment ◽

10.4143/crt.2017.562 ◽

2019 ◽

Vol 51 (1) ◽

pp. 43-52 ◽

Cited By ~ 7

Author(s):

In Hae Park ◽

Seock-Ah Im ◽

Kyung Hae Jung ◽

Joo Hyuk Sohn ◽

Yeon Hee Park ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs18-ot3-02-07 ◽

2019 ◽

Author(s):

O Metzger ◽

S Mandrekar ◽

S Loibl ◽

C Mundhenke ◽

S Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps641 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS641-TPS641 ◽

Cited By ~ 2

Author(s):

Kathy Miller ◽

Javier Cortes ◽

Sara A. Hurvitz ◽

Ian E. Krop ◽

Debu Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1

Annals of Oncology ◽

10.1093/annonc/mdw365.94 ◽

2016 ◽

Vol 27 ◽

pp. vi99

Author(s):

J. Cortes Castan ◽

S. Verma ◽

S. Hurvitz ◽

I.E. Krop ◽

D. Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps631 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS631-TPS631

Author(s):

Kathy Miller ◽

Javier Cortes ◽

Sara A. Hurvitz ◽

Ian E. Krop ◽

Debu Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Abstract P1-12-08: Quality of Life in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes who Received Eribulin Mesylate or Capecitabine in a Phase III, Open-label, Randomized Study

10.1158/0008-5472.sabcs12-p1-12-08 ◽

2012 ◽

Author(s):

Javier Cortes ◽

Ahmad Awada ◽

Christopher Twelves ◽

Louise Yelle ◽

Jantien Wanders ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Eribulin Mesylate ◽